Sst001

Phase 1

SSynusight Biotech (Shanghai) Co., Ltd.

Sst001 is one of 2 therapeutic programs targeting Multiple System Atrophy, MSA. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Multiple System Atrophy, MSARecruiting

Multiple System Atrophy, MSAPhase 1

Recruiting

Competition

Competitive Landscape

1 competitor in Multiple System Atrophy, MSA

#DrugCompanyPhaseTrials

ONO-2808

Ono Pharmaceutical Co. Ltd

Phase 2

1 2

Sst001

SSynusight Biotech (Shanghai) Co., Ltd.

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 1Recruiting

Multiple System Atrophy, MSA

NCT07604116

Clinical

Trials by Indication[1]

Multiple System Atrophy, MSA1 trial

A Non-Randomized, Open-Label Phase I Study to Evaluate the Safety, Tolerability, Biodistribution, Radiation Dosimetry, and Pharmacokinetics of SST001 in Healthy Volunteers, Patients With Multiple System Atrophy, and Patients With Parkinson's Disease

Recruiting·SSynusight Biotech (Shanghai) Co., Ltd.·Phase 1·NCT07604116·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Sst001. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Sst001. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Synusight Biotech (Shanghai) Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 1[1]
Company: SSynusight Biotech (Shanghai) Co., Ltd.

Sst001

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q1 2027

Trials by Indication[1]

Multiple System Atrophy, MSA1 trial

References

Drug Info

Quick Facts

Related News